Patient-derived organoids for the personalized treatment of pancreatic neuroendocrine tumor with liver metastases: A case report

doi:10.4251/wjgo.v17.i11.112385

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 11

This Article

(41)

(73)

(0)

(9)

(739)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastrointest Oncol. Nov 15, 2025; 17(11): 112385
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.112385

Full Size Figure Download Figure

Figure 4 The growth status of organoids from liver metastatic lesions drug sensitivity testing result. FOLFIRI: Folinic acid, fluorouracil, and irinotecan; mFOLFOX6: Modified folinic acid, fluorouracil, and oxaliplatin 6.

Citation: Yang XM, Sun W, He YG, Peng XH, You N, Tang YC, Zheng L, Huang XB. Patient-derived organoids for the personalized treatment of pancreatic neuroendocrine tumor with liver metastases: A case report. World J Gastrointest Oncol 2025; 17(11): 112385
URL: https://www.wjgnet.com/1948-5204/full/v17/i11/112385.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i11.112385

Yang XM, Sun W, He YG, Peng XH, You N, Tang YC, Zheng L, Huang XB. Patient-derived organoids for the personalized treatment of pancreatic neuroendocrine tumor with liver metastases: A case report. World J Gastrointest Oncol 2025; 17(11): 112385 [PMID: 41281488 DOI: 10.4251/wjgo.v17.i11.112385]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.